Structure of SARS-CoV-2 main protease in the apo state

doi:10.1007/s11427-020-1791-3

Comment

. 2021 Apr;64(4):656-659.

doi: 10.1007/s11427-020-1791-3. Epub 2020 Sep 1.

Structure of SARS-CoV-2 main protease in the apo state

Xuelan Zhou^#¹, Fanglin Zhong^#^{2

3}, Cheng Lin^{4

5}, Xiaohui Hu¹, Yan Zhang⁶, Bing Xiong⁷, Xiushan Yin^{8

9}, Jinheng Fu¹⁰, Wei He², Jingjing Duan¹¹, Yang Fu¹², Huan Zhou¹³, Peter J McCormick¹⁴, Qisheng Wang¹⁵, Jian Li^{16

17}, Jin Zhang¹⁸

Affiliations

¹ School of Basic Medical Sciences, Nanchang University, Nanchang, 330031, China.
² College of Pharmaceutical Sciences, Gannan Medical University, Ganzhou, 341000, China.
³ Laboratory of Prevention and Treatment of Cardiovascular and Cerebrovascular Diseases, Ministry of Education, Gannan Medical University, Ganzhou, 341000, China.
⁴ Shenzhen Crystalo Biopharmaceutical Co., Ltd, Shenzhen, 518118, China.
⁵ Jiangxi Jmerry Biopharmaceutical Co., Ltd, Ganzhou, 341000, China.
⁶ The Second Affiliated Hospital of Nanchang University, Nanchang, 330031, China.
⁷ Department of Medicinal Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
⁸ Applied Biology Laboratory, Shenyang University of Chemical Technology, Shenyang, 110142, China.
⁹ Biotech & Biomedicine Science (Jiangxi) Co. Ltd, Ganzhou, 341000, China.
¹⁰ Jiangxi-OAI Joint Research Institution, Nanchang University, Nanchang, 330047, China.
¹¹ Human Aging Research Institute (HARI), School of Life Sciences, Nanchang University, Nanchang, 330031, China.
¹² School of Medicine, Southern University of Science and Technology, Shenzhen, 518055, China.
¹³ Shanghai Synchrotron Radiation Facility, Shanghai Advanced Research Institute, Chinese Academy of Sciences, Shanghai, 201204, China.
¹⁴ Centre for Endocrinology, William Harvey Research Institute, Bart's and the London School of Medicine and Dentistry, Queen Mary, University of London, London, EC1M 6BQ, UK.
¹⁵ Shanghai Synchrotron Radiation Facility, Shanghai Advanced Research Institute, Chinese Academy of Sciences, Shanghai, 201204, China. wangqisheng@zjlab.org.cn.
¹⁶ College of Pharmaceutical Sciences, Gannan Medical University, Ganzhou, 341000, China. rmsl_2040@163.com.
¹⁷ Laboratory of Prevention and Treatment of Cardiovascular and Cerebrovascular Diseases, Ministry of Education, Gannan Medical University, Ganzhou, 341000, China. rmsl_2040@163.com.
¹⁸ School of Basic Medical Sciences, Nanchang University, Nanchang, 330031, China. zhangxiaokong@hotmail.com.

^# Contributed equally.

PMID: 32880863
PMCID: PMC7471536
DOI: 10.1007/s11427-020-1791-3

Comment

Structure of SARS-CoV-2 main protease in the apo state

Xuelan Zhou et al. Sci China Life Sci. 2021 Apr.

. 2021 Apr;64(4):656-659.

doi: 10.1007/s11427-020-1791-3. Epub 2020 Sep 1.

Authors

Affiliations

¹ School of Basic Medical Sciences, Nanchang University, Nanchang, 330031, China.
² College of Pharmaceutical Sciences, Gannan Medical University, Ganzhou, 341000, China.
³ Laboratory of Prevention and Treatment of Cardiovascular and Cerebrovascular Diseases, Ministry of Education, Gannan Medical University, Ganzhou, 341000, China.
⁴ Shenzhen Crystalo Biopharmaceutical Co., Ltd, Shenzhen, 518118, China.
⁵ Jiangxi Jmerry Biopharmaceutical Co., Ltd, Ganzhou, 341000, China.
⁶ The Second Affiliated Hospital of Nanchang University, Nanchang, 330031, China.
⁷ Department of Medicinal Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
⁸ Applied Biology Laboratory, Shenyang University of Chemical Technology, Shenyang, 110142, China.
⁹ Biotech & Biomedicine Science (Jiangxi) Co. Ltd, Ganzhou, 341000, China.
¹⁰ Jiangxi-OAI Joint Research Institution, Nanchang University, Nanchang, 330047, China.
¹¹ Human Aging Research Institute (HARI), School of Life Sciences, Nanchang University, Nanchang, 330031, China.
¹² School of Medicine, Southern University of Science and Technology, Shenzhen, 518055, China.
¹³ Shanghai Synchrotron Radiation Facility, Shanghai Advanced Research Institute, Chinese Academy of Sciences, Shanghai, 201204, China.
¹⁴ Centre for Endocrinology, William Harvey Research Institute, Bart's and the London School of Medicine and Dentistry, Queen Mary, University of London, London, EC1M 6BQ, UK.
¹⁵ Shanghai Synchrotron Radiation Facility, Shanghai Advanced Research Institute, Chinese Academy of Sciences, Shanghai, 201204, China. wangqisheng@zjlab.org.cn.
¹⁶ College of Pharmaceutical Sciences, Gannan Medical University, Ganzhou, 341000, China. rmsl_2040@163.com.
¹⁷ Laboratory of Prevention and Treatment of Cardiovascular and Cerebrovascular Diseases, Ministry of Education, Gannan Medical University, Ganzhou, 341000, China. rmsl_2040@163.com.
¹⁸ School of Basic Medical Sciences, Nanchang University, Nanchang, 330031, China. zhangxiaokong@hotmail.com.

^# Contributed equally.

PMID: 32880863
PMCID: PMC7471536
DOI: 10.1007/s11427-020-1791-3

No abstract available

PubMed Disclaimer

Comment on

Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease.
Dai W, Zhang B, Jiang XM, Su H, Li J, Zhao Y, Xie X, Jin Z, Peng J, Liu F, Li C, Li Y, Bai F, Wang H, Cheng X, Cen X, Hu S, Yang X, Wang J, Liu X, Xiao G, Jiang H, Rao Z, Zhang LK, Xu Y, Yang H, Liu H. Dai W, et al. Science. 2020 Jun 19;368(6497):1331-1335. doi: 10.1126/science.abb4489. Epub 2020 Apr 22. Science. 2020. PMID: 32321856 Free PMC article.
Structural basis for the inhibition of SARS-CoV-2 main protease by antineoplastic drug carmofur.
Jin Z, Zhao Y, Sun Y, Zhang B, Wang H, Wu Y, Zhu Y, Zhu C, Hu T, Du X, Duan Y, Yu J, Yang X, Yang X, Yang K, Liu X, Guddat LW, Xiao G, Zhang L, Yang H, Rao Z. Jin Z, et al. Nat Struct Mol Biol. 2020 Jun;27(6):529-532. doi: 10.1038/s41594-020-0440-6. Epub 2020 May 7. Nat Struct Mol Biol. 2020. PMID: 32382072

Cited by

Identification of medicinal plant-based phytochemicals as a potential inhibitor for SARS-CoV-2 main protease (M^pro) using molecular docking and deep learning methods.
Hossain A, Rahman ME, Rahman MS, Nasirujjaman K, Matin MN, Faruqe MO, Rabbee MF. Hossain A, et al. Comput Biol Med. 2023 May;157:106785. doi: 10.1016/j.compbiomed.2023.106785. Epub 2023 Mar 11. Comput Biol Med. 2023. PMID: 36931201 Free PMC article.
SARS-CoV-2 M^pro: A Potential Target for Peptidomimetics and Small-Molecule Inhibitors.
Citarella A, Scala A, Piperno A, Micale N. Citarella A, et al. Biomolecules. 2021 Apr 19;11(4):607. doi: 10.3390/biom11040607. Biomolecules. 2021. PMID: 33921886 Free PMC article. Review.
Virtual Screening of Peptide Libraries: The Search for Peptide-Based Therapeutics Using Computational Tools.
Vincenzi M, Mercurio FA, Leone M. Vincenzi M, et al. Int J Mol Sci. 2024 Feb 1;25(3):1798. doi: 10.3390/ijms25031798. Int J Mol Sci. 2024. PMID: 38339078 Free PMC article. Review.
Computer-Aided Screening for Potential Coronavirus 3-Chymotrypsin-like Protease (3CLpro) Inhibitory Peptides from Putative Hemp Seed Trypsinized Peptidome.
Prasertsuk K, Prongfa K, Suttiwanich P, Harnkit N, Sangkhawasi M, Promta P, Chumnanpuen P. Prasertsuk K, et al. Molecules. 2022 Dec 21;28(1):50. doi: 10.3390/molecules28010050. Molecules. 2022. PMID: 36615263 Free PMC article.
High-resolution mining of the SARS-CoV-2 main protease conformational space: supercomputer-driven unsupervised adaptive sampling.
Jaffrelot Inizan T, Célerse F, Adjoua O, El Ahdab D, Jolly LH, Liu C, Ren P, Montes M, Lagarde N, Lagardère L, Monmarché P, Piquemal JP. Jaffrelot Inizan T, et al. Chem Sci. 2021 Feb 2;12(13):4889-4907. doi: 10.1039/d1sc00145k. Chem Sci. 2021. PMID: 34168762 Free PMC article.

See all "Cited by" articles

References

1. Dai W, Zhang B, Jiang XM, Su H, Li J, Zhao Y, Xie X, Jin Z, Peng J, Liu F, et al. Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease. Science. 2020;368:1331–1335. doi: 10.1126/science.abb4489. - DOI - PMC - PubMed
1. Hilgenfeld R. From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design. FEBS J. 2014;281:4085–4096. doi: 10.1111/febs.12936. - DOI - PMC - PubMed
1. Jin Z, Du X, Xu Y, Deng Y, Liu M, Zhao Y, Zhang B, Li X, Zhang L, Peng C, et al. Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors. Nature. 2020;582:289–293. doi: 10.1038/s41586-020-2223-y. - DOI - PubMed
1. Jin Z, Zhao Y, Sun Y, Zhang B, Wang H, Wu Y, Zhu Y, Zhu C, Hu T, Du X, et al. Structural basis for the inhibition of SARS-CoV-2 main protease by antineoplastic drug carmofur. Nat Struct Mol Biol. 2020;27:529–532. doi: 10.1038/s41594-020-0440-6. - DOI - PubMed
1. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, Wang W, Song H, Huang B, Zhu N, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395:565–574. doi: 10.1016/S0140-6736(20)30251-8. - DOI - PMC - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal

[1] Dai W, Zhang B, Jiang XM, Su H, Li J, Zhao Y, Xie X, Jin Z, Peng J, Liu F, et al. Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease. Science. 2020;368:1331–1335. doi: 10.1126/science.abb4489. - DOI - PMC - PubMed

[2] Dai W, Zhang B, Jiang XM, Su H, Li J, Zhao Y, Xie X, Jin Z, Peng J, Liu F, et al. Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease. Science. 2020;368:1331–1335. doi: 10.1126/science.abb4489. - DOI - PMC - PubMed

[3] Hilgenfeld R. From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design. FEBS J. 2014;281:4085–4096. doi: 10.1111/febs.12936. - DOI - PMC - PubMed

[4] Hilgenfeld R. From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design. FEBS J. 2014;281:4085–4096. doi: 10.1111/febs.12936. - DOI - PMC - PubMed

[5] Jin Z, Du X, Xu Y, Deng Y, Liu M, Zhao Y, Zhang B, Li X, Zhang L, Peng C, et al. Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors. Nature. 2020;582:289–293. doi: 10.1038/s41586-020-2223-y. - DOI - PubMed

[6] Jin Z, Du X, Xu Y, Deng Y, Liu M, Zhao Y, Zhang B, Li X, Zhang L, Peng C, et al. Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors. Nature. 2020;582:289–293. doi: 10.1038/s41586-020-2223-y. - DOI - PubMed

[7] Jin Z, Zhao Y, Sun Y, Zhang B, Wang H, Wu Y, Zhu Y, Zhu C, Hu T, Du X, et al. Structural basis for the inhibition of SARS-CoV-2 main protease by antineoplastic drug carmofur. Nat Struct Mol Biol. 2020;27:529–532. doi: 10.1038/s41594-020-0440-6. - DOI - PubMed

[8] Jin Z, Zhao Y, Sun Y, Zhang B, Wang H, Wu Y, Zhu Y, Zhu C, Hu T, Du X, et al. Structural basis for the inhibition of SARS-CoV-2 main protease by antineoplastic drug carmofur. Nat Struct Mol Biol. 2020;27:529–532. doi: 10.1038/s41594-020-0440-6. - DOI - PubMed

[9] Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, Wang W, Song H, Huang B, Zhu N, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395:565–574. doi: 10.1016/S0140-6736(20)30251-8. - DOI - PMC - PubMed

[10] Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, Wang W, Song H, Huang B, Zhu N, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395:565–574. doi: 10.1016/S0140-6736(20)30251-8. - DOI - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Structure of SARS-CoV-2 main protease in the apo state

Affiliations

Structure of SARS-CoV-2 main protease in the apo state

Authors

Affiliations

Comment on

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Miscellaneous

Comment on

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources

Medical

Miscellaneous